|
Pronunciation |
|
(deks
klor fen EER a
meen) |
|
|
U.S. Brand
Names |
|
Dexchlor®; Poladex®;
Polaramine® |
|
|
Generic
Available |
|
Yes |
|
|
Synonyms |
|
Dexchlorpheniramine Maleate |
|
|
Pharmacological Index |
|
Antihistamine |
|
|
Use |
|
Perennial and seasonal allergic rhinitis and other allergic symptoms
including urticaria |
|
|
Pregnancy Risk
Factor |
|
B |
|
|
Contraindications |
|
Narrow-angle glaucoma, hypersensitivity to dexchlorpheniramine or any
component |
|
|
Warnings/Precautions |
|
Bladder neck obstruction, symptomatic prostatic hypertrophy, asthmatic
attack, and stenosing peptic ulcer |
|
|
Adverse
Reactions |
|
>10%:
Central nervous system: Slight to moderate drowsiness
Respiratory: Thickening of bronchial secretions
1% to 10%:
Central nervous system: Headache, fatigue, nervousness, dizziness
Gastrointestinal: Appetite increase, weight increase, nausea, diarrhea,
abdominal pain, xerostomia
Neuromuscular & skeletal: Arthralgia
Respiratory: Pharyngitis |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include dry mouth, flushed skin, dilated pupils, CNS
depression. There is no specific treatment for antihistamine overdose. Clinical
toxicity is due to blockade of cholinergic receptors. For anticholinergic
overdose with severe life-threatening symptoms, physostigmine 1-2 mg I.V.
slowly, may be given to reverse these effects. |
|
|
Drug
Interactions |
|
Increased effect/toxicity: CNS depressants, MAO inhibitors, TCAs,
phenothiazines, guanabenz |
|
|
Mechanism of
Action |
|
Competes with histamine for H1-receptor sites on effector cells in
the gastrointestinal tract, blood vessels, and respiratory
tract |
|
|
Pharmacodynamics/Kinetics |
|
Onset of action: ~1 hour
Duration: 3-6 hours
Absorption: Well absorbed from GI tract |
|
|
Usual Dosage |
|
Oral:
2-5 years: 0.5 mg every 4-6 hours (do not use timed release)
6-11 years: 1 mg every 4-6 hours or 4 mg timed release at bedtime
Adults: 2 mg every 4-6 hours or 4-6 mg timed release at bedtime or every 8-10
hours |
|
|
Dietary
Considerations |
|
May be administered with food or water |
|
|
Mental Health: Effects
on Mental Status |
|
Drowsiness is common; may cause nervousness and
depression |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Concurrent use with psychotropics may cause additive
sedation |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
Up to 10% of patients will complain of significant dry mouth and drowsiness.
This will disappear with cessation of drug therapy. |
|
|
Patient
Information |
|
Take as directed; do not exceed recommended dose. Do not chew or crush
sustained release tablet. Avoid use of other depressants, alcohol, or
sleep-inducing medications unless approved by prescriber. You may experience
drowsiness or dizziness (use caution when driving or engaging in tasks requiring
alertness until response to drug is known); or dry mouth, nausea, or abdominal
pain (frequent small meals, frequent mouth care, chewing gum, or sucking hard
candy may help). Report persistent sedation, confusion, or agitation; changes in
urinary pattern; blurred vision; sore throat, difficulty breathing or
expectorating (thick secretions); or lack of improvement or worsening or
condition. Breast-feeding precautions: Breast-feeding is not
recommended. |
|
|
Nursing
Implications |
|
May cause drowsiness; swallow whole, do not crush or chew sustained release
product; avoid alcohol, may impair coordination and
judgment |
|
|
Dosage Forms |
|
Syrup, as maleate (orange flavor): 2 mg/5 mL with alcohol 6% (480 mL)
Tablet, as maleate: 2 mg
Tablet, as maleate, sustained action: 4 mg, 6 mg
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|